United States · Funded startup
9 rounds we have observed, with the 6 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$92Mraised across 9 rounds since 2006, from 9 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
No investor was named in the report.
From a historical funding recordSEC filing: $52M sold, first sale Jun 2015
No investor was named in the report.
From a historical funding recordSEC filing: $326K sold, first sale Feb 2014
No investor was named in the report.
Reported by sec.govSEC filing: $1.3M sold, first sale Jun 2013
No investor was named in the report.
Reported by sec.govSEC filing: $250K sold, first sale Dec 2012
No investor was named in the report.
Reported by sec.govSEC filing: $325K sold, first sale Oct 2012
No investor was named in the report.
Reported by sec.govSEC filing: $4.5M sold, first sale Dec 2011
No investor was named in the report.
From a historical funding recordSEC filing: $500K sold, first sale Oct 2009
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Atlas Venture
Boulder Ventures
InterWest PartnersPequot Capital
Skyline VenturesPeierls FoundationMissing a round, or an investor who was in one? Tell us.
ARCA biopharma's investors include Atlas Venture, Boulder Ventures, InterWest Partners, Pequot Capital and Skyline Ventures, and 1 more on record.
ARCA biopharma has raised $92M across 9 rounds since 2006.
ARCA biopharma's most recent round was an Undisclosed round of $52M in Jun 2015.
Its most recent round, $52M in Jun 2015, is also its largest on record.
ARCA biopharma's first round on record, in Mar 2006, was backed by Atlas Venture, Boulder Ventures and Pequot Capital.
ARCA biopharma's latest named round is an Undisclosed round, in Jun 2015.
ARCA biopharma is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States ·